Prolonged activation of prothrombin on the vascular wall after arterial injury.
This study was designed to characterize the relative roles of bound Xa/Va and thrombin activity in vascular wall procoagulant activity after balloon-induced injury and the extent to which intravenous aspirin and heparin attenuate procoagulant activity associated with the vascular wall. Abdominal aortic injury was induced in rabbits by overinflation and multiple passages ofa 4F embolectomy catheter. Rabbits were killed 15 minutes or 4, 8, 24, 48, 72, 96, or 120 hours after injury. Aortic segments were incubated ex vivo to define bound procoagulant activity. Thrombin activity bound to the aorta was detected by 4 hours after injury and was most marked over the first 24 hours, as estimated by increases in concentration of fibrinopeptide A during incubation of segments with recalcified barium-adsorbed plasma or activity against the thrombin-synthetic substrate S-2238. Based on comparison with purified human thrombin incubated under the same conditions, a maximum of 0.04 to 0.1 nmol/L per square centimeter of thrombin activity was associated with the vascular wall during the first 24 hours and remained detectable for 72 hours. In contrast, bound Xa/Va complex activity to injured segments was detected within 15 minutes and induced activation of prothrombin added to recalcified barium-adsorbed plasma incubated with injured segments for 96 hours. Aspirin (15 mg/kg) administered 30 minutes before injury attenuated 111In-platelet deposition at 4 hours by 67%, with an associated decrease in bound Xa/Va and thrombin activity at 15 minutes and 4 hours. However, intravenous heparin did not attenuate bound Xa/Va activity at 15 minutes or thrombin activity at 15 minutes and 4 hours. Platelet-dependent bound Xa/Va activity occurs rapidly after arterial injury and may promote thrombin elaboration for up to 96 hours. Bound thrombin activity and de novo thrombin elaboration on the vascular wall may play an important role in the progression of thrombosis and vascular wall remodeling.
Ghigliotti
G
G
Cardiovascular Division, Washington University School of Medicine, St Louis, Mo 63110, USA.
Waissbluth
A R
AR
Speidel
C
C
Abendschein
D R
DR
Eisenberg
P R
PR
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D001158:Arteries / Q000293:injuries* / Q000378:metabolism / Q000503:physiopathology*; D001241:Aspirin / Q000494:pharmacology; D001779:Blood Coagulation Factors / Q000378:metabolism / Q000502:physiology; D001792:Blood Platelets / Q000502:physiology; D005170:Factor X / Q000502:physiology; D015951:Factor Xa / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011516:Prothrombin / Q000502:physiology*; D011817:Rabbits; D013917:Thrombin / Q000378:metabolism; D013997:Time Factors; D014949:Wounds, Nonpenetrating / Q000378:metabolism / Q000503:physiopathology*
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D010975:Platelet Aggregation Inhibitors; C045071:leukocyte procoagulant activity; D011516:Prothrombin; D005170:Factor X; D006493:Heparin; D013917:Thrombin; D015951:Factor Xa; D001241:Aspirin